



## Manufacturers' Forum ANNOUNCEMENT NorthStar HealthCare Consulting Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum for the **February 2023 DURB Meeting**.

**Appointments: *The Manufacturers' Forum is by appointment only and will be conducted virtually.*** Appointments may be requested and will be scheduled **after** the Drugs Under Review are posted to the DCH website at <https://dch.georgia.gov/providers/provider-types/pharmacy/drug-utilization-review-board>. ***Only manufacturers with drugs up for review at the current DURB meeting will be granted appointments at this Forum.*** All requests for appointments must be made in writing to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) and include the drug name. **New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

### Guidelines for Participation:

- Individual manufacturer participation shall be limited to one 60-minute time segment per Forum. The presentation shall be limited to approximately 40 minutes with 20 minutes for questions and answers.
- An electronic **one-page** summary (front only, font 10, not including references) of each drug presentation, **factually based**, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com). Please include a pronunciation guide of the drug's brand and generic names. The one-page summary may be provided to the DURB members.

### Helpful Information for Manufacturers with non-DURB Drugs:

- Manufacturers with *new drugs* that are *not* under review at the current DURB meeting are requested to wait until their drug is under review to request Forum participation.
- Manufacturers with *new drugs* that have *orphan designation* are highly encouraged to share any noteworthy information regarding their drug for review by DCH and NHC electronically, as these drugs are typically reviewed internally by DCH in lieu of the DURB. Please follow the one-page summary format explained above and send to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com).
- Manufacturers seeking appointments for drugs that are currently listed on the Preferred Drug List (PDL) and/or the Providers' Administered Drug List (PADL) will be granted appointments at a future Forum or on an *ad hoc* basis at DCH/NHC's discretion. Regardless of whether an appointment is granted, all manufacturers are encouraged to send relevant, pertinent clinical information electronically to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com) for review. Please follow the one-page summary format described above.

### Comments and Inquiries:

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **Preferred Drug List, Prior Authorization Criteria, Manufacturers' Forum or DURB** should submit these in writing to [GAMedicaid@nhc-llc.com](mailto:GAMedicaid@nhc-llc.com).
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **claims processing** or **drug benefit plan design** should submit these in writing to [Tami.Sweat@optum.com](mailto:Tami.Sweat@optum.com).
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS **supplemental rebates** should submit these in writing to [Georgia-DURB@magellanhealth.com](mailto:Georgia-DURB@magellanhealth.com).